New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
07:19 EDTMDVN, ALPMYMedivation, Astellas Pharma submit sNDA for XTANDI
Astellas Pharma (ALPMY) and Medivation (MDVN) announced the submission of a supplemental New Drug Application, or sNDA, to the FDA seeking approval of XTANDI capsules for the treatment of men with metastatic castration-resistant prostate cancer, or mCRPC, who have not received chemotherapy. XTANDI is currently approved for the treatment of patients with mCRPC who have previously received docetaxel chemotherapy. The sNDA application is based on the results from the Phase 3 PREVAIL trial evaluating XTANDI as compared to placebo in more than 1,700 chemotherapy-na´ve mCRPC patients. The marketing authorization application is expected to be submitted to the European Medicines Agency later this year.
News For MDVN;ALPMY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 10, 2016
09:51 EDTALPMYAstellas Pharma completes tender offer to acquire all Ocata Therapeutics shares
Astellas Pharma (ALPMY) announced that it has successfully completed, through its indirect wholly-owned subsidiary Laurel Acquisition, a tender offer to purchase all issued and outstanding shares of common stock of Ocata Therapeutics (OCAT) for a price of $8.50 per share net to the stockholder in cash. Astellas commenced the Tender Offer on November 19, 2015, U.S. Eastern Time, and the Tender Offer, as previously extended, expired at 5:00 p.m., U.S. Eastern Time, on February 9, 2016, and was not further extended. The board of Astellas approved the Tender Offer on November 10, 2015.
February 5, 2016
09:26 EDTMDVNLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
06:05 EDTMDVNMedivation resumed with a Market Perform at Leerink
Subscribe for More Information
February 4, 2016
16:36 EDTMDVNMedivation reinitiated with a Market Perform at Leerink
Target $41.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use